series-b
Stage
2020
Founded
3
Investors
About
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potential best-in-class small molecules and antibody-drug conjugates (ADCs), with lead candidates targeting cyclin-dependent kinases CDK2 and CDK4, and EGFR/HER3 pathways in solid tumors.
Explore avenzo therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.